Clinical quantitative coronary artery stenosis and coronary atherosclerosis imaging: a Consensus Statement from the Quantitative Cardiovascular Imaging Study Group

Autor: Mézquita, AJV, Biavati, F, Falk, V, Alkadhi, H, Hajhosseiny, R, Maurovich-Horvat, P, Manka, R, Kozerke, S, Stuber, M, Derlin, T, Channon, KM, Išgum, I, Coenen, A, Foellmer, B, Dey, D, Volleberg, RHJA, Meinel, FG, Dweck, MR, Piek, JJ, van de Hoef, T, Landmesser, U, Guagliumi, G, Giannopoulos, AA, Botnar, RM, Khamis, R, Williams, MC, Newby, DE, Dewey, M

Publikováno v: Mézquita, A J V, Biavati, F, Falk, V, Alkadhi, H, Hajhosseiny, R, Maurovich-Horvat, P, Manka, R, Kozerke, S, Stuber, M, Derlin, T, Channon, K M, Išgum, I, Coenen, A, Foellmer, B, Dey, D, Volleberg, R H J A, Meinel, F G, Dweck, M R, Piek, J J, Van de Hoef, T, Landmesser, U, Guagliumi, G, Giannopoulos, A A, Botnar, R M, Khamis, R, Williams, M C, Newby, D E & Dewey, M 2023, ' Clinical quantitative coronary artery stenosis and coronary atherosclerosis imaging: a Consensus Statement from the Quantitative Cardiovascular Imaging Study Group ', Nature Reviews Cardiology . https://doi.org/10.1038/s41569-023-00880-4

The detection and characterization of coronary artery stenosis and atherosclerosis using imaging tools are key for clinical decision-making in patients with known or suspected coronary artery disease. In this regard, imaging-based quantification can

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::b5d3ca121f66c3898b95aff8ca39f6fd
https://ora.ox.ac.uk/objects/uuid:ecbe474d-3431-4944-8967-049ddb786b60

Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): Does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)?

Autor: Regier, M., Derlin, T., Schwarz, D., Laqmani, A., Henes, F.O., Groth, M., Buhk, J.-H., Kooijman, H., Adam, G.

Publikováno v: In European Journal of Radiology October 2012 81(10):2913-2918

Clinical Molecular Imaging of Pulmonary CXCR4 Expression to Predict Outcome of Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis

Autor: Derlin, T., Jaeger, B., Jonigk, D., Apel, R.M., Freise, J., Shin, H.-O., Weiberg, D., Warnecke, G., Ross, T.L., Wester, H.-J., Seeliger, B., Welte, T., Bengel, F.M., Prasse, A.

Background. Idiopathic pulmonary fibrosis (IPF) is a progressive disease for which two antifibrotic drugs recently were approved. However, an unmet need exists to predict responses to antifibrotic treatment, such as pirfenidone. Recent data suggest t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______610::45008bc5505860b704b9a5d90c1eedb3
https://publica.fraunhofer.de/handle/publica/268091

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.